Press Releases CF Foundation Provides Up to $8.5M to SpliSense to Support a Clinical Trial for a Potential Treatment for Splicing Mutations Read More »
Press Releases SpliSense Announces FDA Clearance of Investigational New Drug Application for Phase 2 Initiation of SPL84 for the Treatment of Cystic Fibrosis Read More »
Press Releases SpliSense is excited to share its most recent press release, announcing the successful completion a first-in-human, Phase 1 clinical trial of SPL84, the company’s lead anti sense oligonucleotide (ASO) product for the treatment of patients with CF, carrying the unmet 3849-splicing mutation. Read More »
Press Releases SpliSense Initiates Phase 1/2 Study of SPL84, RNA-Based Therapy, for the Treatment of Cystic Fibrosis Read More »
Press Releases First Clinical Trial Begins for RNA-based Therapy SPL84 for CF ,SpliSense treatment would be first for certain CF splicing mutation Read More »
Press Releases Israeli firm SpliSense moves to clinical trials for cystic fibrosis treatment Read More »
Press Releases SpliSense Presents Preclinical Data for SPL23-ASO, mRNA-Altering Drug Candidate for the Treatment of Cystic Fibrosis, at the European Cystic Fibrosis Conference SpliSense Presents Preclinical Data for SPL23-ASO, mRNA-Altering Drug Candidate for the Treatment of Cystic Fibrosis, at the European Cystic Fibrosis Conference Read More »
